Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
| ▸ | CCL5 | P13501 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608899 | 1.00 | CCR5 (0.37) | CCR5KCNH2CCL5CYP3A4CYP2D6 | |
| SCHEMBL5130540 | 1.00 | CCR5 (0.37) | CCR5KCNH2CCL5CYP3A4CYP2D6 | |
| SCHEMBL3604754 | 0.87 | CCR5 (0.47) | CCR5KCNH2 | |
| SCHEMBL3306898 | 0.80 | CCR5 (0.38) | CCR5KCNH2CCL5CYP3A4CYP2D6 | |
| SCHEMBL3304112 | 0.80 | CCR5 (0.38) | CCR5KCNH2CCL5CYP3A4CYP2D6 | |
| SCHEMBL3604590 | 0.80 | CCR5 (0.51) | CCR5KCNH2CCL5CYP3A4CYP2D6 | |
| SCHEMBL3613542 | 0.79 | DPP4 (0.45) | CCR5KCNH2CCL5CYP3A4CYP2D6 | |
| SCHEMBL13393828 | 0.75 | CCR5 (0.46) | CCR5KCNH2CCL5CYP3A4CYP2D6 | |
| SCHEMBL3591589 | 0.75 | CCR5 (0.43) | CCR5KCNH2CCL5CYP3A4CYP2D6 | |
| SCHEMBL3595607 | 0.69 | CCR5 (0.56) | CCR5KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099708-A1 | Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20080139612-A1 | Chemical Compound | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139612-A1 | Chemical Compound | CCR5, CCR2, CXCR3 | CCR5 1/4885KCNH2 2251/4885CCL5 5/4885 |
| US-20100099708-A1 | Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases | CCR5, CXCR5, CCR2 | CCR5 1/4885KCNH2 2562/4885CCL5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.